<HTML xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en" dir="ltr">
<style type="text/css">
A:before { content:' '; } 
A:after { content:' '; } 
SPAN:before { content:' '; } 
SPAN:after { content:' '; } 
</style>
<BODY class="mediawiki  ltr ns-0 ns-subject page-Team_BGU_Israel_Project_Metabolic_Syndrome"><DIV id="globalWrapper"><DIV id="top-section"><DIV id="p-logo"><A href="/Main_Page" title="Main Page">&quot;
	    </A></DIV><DIV id="menubar" class="left-menu noprint"><UL><LI class="selected"><A href="/Team:BGU_Israel/Project/Metabolic_Syndrome">Page               </A></LI><LI class="new"><A href="/wiki/index.php?title=Talk:Team:BGU_Israel/Project/Metabolic_Syndrome&amp;action=edit&amp;redlink=1">Discussion               </A></LI><LI><A href="/wiki/index.php?title=Team:BGU_Israel/Project/Metabolic_Syndrome&amp;action=edit">View source               </A></LI><LI><A href="/wiki/index.php?title=Team:BGU_Israel/Project/Metabolic_Syndrome&amp;action=history">History               </A></LI><LI style="color:white;cursor:default">teams</LI></UL></DIV><DIV class="right-menu noprint" id="menubar"><UL><LI id="pt-login"><A href="/wiki/index.php?title=Special:UserLogin&amp;returnto=Team:BGU_Israel/Project/Metabolic_Syndrome" title="You are encouraged to log in; however, it is not mandatory [o]" accesskey="o">Log in</A></LI></UL></DIV><DIV id="search-controls" class="noprint"><FORM action="/Special:Search" id="searchform"> </FORM></DIV></DIV><DIV id="content"><H1 class="firstHeading">Team:BGU Israel/Project/Metabolic Syndrome</H1><DIV id="bodyContent"><H3 id="siteSub" class="noprint">From 2014.igem.org</H3><DIV class="page1" id="top" style="white-space:nowrap; text-wrap:normal;"><NAV id="main_nav"><DIV id="main_wrap"><UL id="menu_ul"><LI><A href="https://2014.igem.org/Team:BGU_Israel/Team1">Team</A></LI><LI><A href="https://2014.igem.org/Team:BGU_Israel/Team1">Team</A></LI><LI><A href="https://igem.org/Team.cgi?year=2014&amp;team_name=BGU_Israel">Official Team Profile</A></LI><LI><A href="https://2014.igem.org/Team:BGU_Israel/Team/Collaboration">Collaboration</A></LI></UL><LI><A href="https://2014.igem.org/Team:BGU_Israel/Project1">Project</A></LI><LI><A href="https://2014.igem.org/Team:BGU_Israel/Project1">Project Home</A></LI><LI><A href="https://2014.igem.org/Team:BGU_Israel/Project/Metabolic_Syndrome

">The Metabolic Syndrome</A></LI><LI><A href="https://2014.igem.org/Team:BGU_Israel/Project/Aspiration_Shift">Aspiration Shift</A></LI><LI><A href="https://2014.igem.org/Team:BGU_Israel/Project/Artificial_Exercise">Artificial Exercise</A></LI><LI><A href="https://2014.igem.org/Team:BGU_Israel/Project/Hormone_Workshop">Hormone Workshop</A></LI><LI><A href="https://2014.igem.org/Team:BGU_Israel/Project/Intelligent_Medication">Intelligent Medication</A></LI><LI><A href="https://2014.igem.org/Team:BGU_Israel/Achivements">Achivements</A></LI><LI><A style="padding-left:3px" href="https://2014.igem.org/Team:BGU_Israel/Human_Practice1"> Policy &amp; Practices </A></LI><LI><A href="https://2014.igem.org/Team:BGU_Israel/Human_Practice1">P &amp; P Home</A></LI><LI><A href="https://2014.igem.org/Team:BGU_Israel/Human_Practice/Bedouins">Bedouin Campaign</A></LI><LI><A href="
https://2014.igem.org/Team:BGU_Israel/Human_Practice/Spread_The_Word">Inner Doctor Campaign</A></LI><LI><A href="https://2014.igem.org/Team:BGU_Israel/Human_Practice/University_Outreach">University Outreach</A></LI><LI><A href="https://2014.igem.org/Team:BGU_Israel/Human_Practice/Target">Target Population</A></LI><LI><A href="https://2014.igem.org/Team:BGU_Israel/Human_Practice/Policies">Laws &amp; Regulations</A></LI><LI><A href="https://2014.igem.org/Team:BGU_Israel/Human_Practice/Ethics">Ethics</A></LI><LI><A href="https://2014.igem.org/Team:BGU_Israel/Human_Practice/Project_Assessment">Project Assessment</A></LI><LI><A href="https://2014.igem.org/Team:BGU_Israel/Parts1">Parts</A></LI><LI><A href="#">Modeling⇓</A></LI><LI><A href="https://2014.igem.org/Team:BGU_Israel/Modeling/scRNA">scRNA Model</A></LI><LI><A href="https://2014.igem.org/Team:BGU_Israel/Modeling/Aspiration_Shift">Aspiration Shift Model</A></LI><LI><A href="https://2014.igem.org/Team:BGU_Israel/Notebook1">Notebook</A></LI><LI><A href="https://2014.igem.org/Team:BGU_Israel/Notebook1">Notebook</A></LI><LI><A href="https://2014.igem.org/Team:BGU_Israel/Safety/Lab_Protocols">Lab Protocols</A></LI><LI><A href="https://2014.igem.org/Team:BGU_Israel/Safety1">Safety</A></LI><LI><A href="https://2014.igem.org/Team:BGU_Israel/Attributions1">Attributions</A></LI></DIV></NAV><SECTION><DIV class="col3" style="margin-right:20px;height: 190px; width: 507px;"><H3 style="border-bottom:dashed;border-color:#000000">Background</H3>
A cluster of cardiometabolic risk factors, including central obesity and insulin resistance, which is diagnosed in quarter of the world adult population.

        </DIV><DIV class="col3" style="margin-right:16px; height: 190px; margin-right: 0px; width: 507px;"><H3 style="border-bottom:dashed;border-color:#000000">Current Treatment </H3>
There are a lot of medications for the many symptoms of the syndrome, most of them are associated with a lot of side effects, especially in combination of different of drugs.

        </DIV><DIV class="textCont" style="height: 540px;"><H3 style="border-bottom:dashed;border-color:#000000">Background </H3><DIV class="col2"><P>The metabolic syndrome (MetS) is a cluster of cardiometabolic risk factors including central obesity, insulin resistance, glucose intolerance, dyslipidaemia and raised blood pressure [1]. The international Diabetes Federation (IDF) declared the syndrome ass a combination of the most dangerous risk factors for heart attack [2], which is the leading cause of death in high- or middle-income countries. The prevalence of MetS is increasing worldwide due to the epidemic of overweight and obesity. Today, it is estimated that 20-25% of the world's adult population suffers from MetS.</P></DIV><DIV class="col2"><P>People with MetS have fivefold greater risk of developing type 2 diabetes (T2D) [3], the most common chronic diseases worldwide and the fourth or fifth leading cause of death in the developed world. Many factors can lead to development of MeS, Genetics, physical inactivity, ageing, a proinflammatory state and hormonal changes, all can have a casual effect depending on ethnic group [4]. However the insulin resistance and central obesity considered the most significant factors.</P></DIV></DIV><DIV class="textCont" style="height: 170px; margin-bottom: 12px;"><H3 style="border-bottom:dashed;border-color:#000000">Insulin Resistance</H3><P>Insulin resistance occurs when many cells in specific tissues (liver, skeletal muscle and adipose) become less sensitive to insulin and eventually become resistance to it. The absorption of glucose declines and its level in the blood is rising. This triggers the pancreas to produce more insulin in attempt to process the glucose. Once the pancreas is no longer able to produce enough insulin, the person become hyperglycemic and will be diagnosed with type 2 diabetes.</P></DIV><DIV class="textCont" style="height: 150px; margin-bottom: 12px;"><H3 style="border-bottom:dashed;border-color:#000000">Central Obesity</H3><P>Obesity strongly contributes to hypertension, high serum cholesterol, low HDL and hyperglycemia. An increment in body mass index (BMI) and especially excess of body fat in the abdomen, raise the risk for serious health consequences in the form of type 2 diabetes, coronary heart disease, cardiovascular disease (CVD) and even cancer [5].</P></DIV><DIV class="textCont" style="height: 420px; margin-bottom: 12px;"><H3 style="border-bottom:dashed;border-color:#000000">Current Treatment and Side Effects</H3><DIV class="col2"><P>Because MetS is a cluster of many disorders, there many kinds of medication for each of the symptoms. Statins for example are a group of chemicals which inhibits the synthesis of cholesterol in the liver. Although intensive-dose statin therapy was associated with a reduced risk for CVD, it was also associated with an increased risk for statin-induced adverse events [6]. There are many kinds of insulin sensitizers, the most prominent are Metformin has showed to be delaying in devepment of T2D by the Diabetes Prevention Program (DPP). However like many other sensitizers it influences the whole body. The fact that only specific tissues in the body resistance to insulin (which is also a strong growth factor), makes a high dose treatment very risky. Other drugs like fibrates, Angiotensin inhibitor and Thiazolidinedione, all treat a specific symptom but not the cause of the Disease, and the biggest problem is that combination of them many times can lead to serious side effects.</P></DIV><DIV class="col2"><P>Therapeutic Lifestyle Changes (TLC) is considered the most beneficial way to prevent or at least delay T2D and CVD.  TLC also showed better results in the DPP that drugs therapy [7]. On the other hand, a proper diet and permanent exercise program demand knowledge and ambition, which not always accessible to unhealthy people. </P><P>We see the MeS as a growing Epidemic which is crossing countries and ethnics groups. A disease in this scale is worth a better treatment, one without dangerous side effects, which will treat the factors that cause the disorders and not just improve a specific symptom.</P></DIV></DIV><DIV class="textCont" style="height: 310px; margin-bottom: 12px; min-height: 2px;"><H3 style="border-bottom:dashed;border-color:#000000">References </H3><OL><LI>Kassi  E, Pervanidou P, Kaltsas G, Chrousos G (2011) Metabolic syndrome: definitions  and controversies. BMC Med 9:48</LI><LI>http://www.idf.org</LI><LI>Stern  M, Williams K, Gonzalez-Villalpando C et al. Does the metabolic syndrome improve  identifi cation of individuals at risk of type 2 diabetes and/or cardiovascular  disease? Diabetes Care 2004 ;27(11):2676-81</LI><LI>Anderson  PJ, Critchley JAJH, Chan JCN et al. Factor analysis of the metabolic syndrome:  obesity vs insulin resistance as the central abnormality. International Journal  of Obesity 2001 ;25:1782</LI><LI>Lee  IM, Manson JE, Hennekens CH et al. Body weight and mortality. A 27-year follow up  of middle-aged men. JAMA 1993;270:2823-8</LI><LI>Meta-analysis  of drug-induced adverse events associated with intensive-dose statin therapy.</LI><LI>Long-Term Safety, Tolerability, and Weight Loss  Associated With Metformin in the Diabetes Prevention Program Outcomes Study </LI></OL><P> </P></DIV></SECTION></DIV><DIV class="printfooter">
Retrieved from &quot;<A href="http://2014.igem.org/Team:BGU_Israel/Project/Metabolic_Syndrome">http://2014.igem.org/Team:BGU_Israel/Project/Metabolic_Syndrome</A>&quot;</DIV></DIV></DIV><DIV id="footer-box" class="noprint"><DIV id="footer"><UL id="f-list"><LI id="t-recentchanges"><A href="/Special:RecentChanges" title="Recent changes">Recent changes</A></LI><LI id="t-whatlinkshere"><A href="/Special:WhatLinksHere/Team:BGU_Israel/Project/Metabolic_Syndrome" title="List of all wiki pages that link here [j]" accesskey="j">What links here</A></LI><LI id="t-recentchangeslinked"><A href="/Special:RecentChangesLinked/Team:BGU_Israel/Project/Metabolic_Syndrome" title="Recent changes in pages linked from this page [k]" accesskey="k">Related changes</A></LI><LI id="t-specialpages"><A href="/Special:SpecialPages" title="List of all special pages [q]" accesskey="q">Special pages</A></LI><LI><A href="/Special:Preferences">My preferences</A></LI></UL></DIV><DIV id="footer"><UL id="f-list"><LI id="t-print"><A href="/wiki/index.php?title=Team:BGU_Israel/Project/Metabolic_Syndrome&amp;printable=yes" title="Printable version of this page [p]" accesskey="p">Printable version</A></LI><LI id="t-permalink"><A href="/wiki/index.php?title=Team:BGU_Israel/Project/Metabolic_Syndrome&amp;oldid=369287" title="Permanent link to this revision of the page">Permanent link</A></LI><LI id="privacy"><A href="/2014.igem.org:Privacy_policy" title="2014.igem.org:Privacy policy">Privacy policy</A></LI><LI id="disclaimer"><A href="/2014.igem.org:General_disclaimer" title="2014.igem.org:General disclaimer">Disclaimers</A></LI></UL></DIV></DIV></DIV></BODY></HTML>